Over the past 40 years, substantial progress has been made in the discovery of PDE4 inhibitors as therapeutic agents, producing an exhaustive set of preclinical and clinical data which widely supports drug discovery programs on new treatments for inflammatory-based diseases, such as COPD, asthma and psoriasis. Here, PDE4A is linked to asthma.